Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Doxorubicin 17Cyclophosphamide 16Ifosfamide 11fludarabine 9Radiotherapy 8tazemetostat 5pembrolizumab 4pazopanib 4Gemcitabine 4pegfilgrastim 3cixutumumab 3Trabectedin 3Radiation 3Imatinib Mesylate 3Filgrastim 3Docetaxel 3Dacarbazine 3sargramostim 2liposomal doxorubicin 2fludarabine phosphate 2brostallicin 2aldesleukin 2X-Rays 2Sunitinib 2Specimen Handling 2Sorafenib 2Radiation Dose Hypofractionation 2Quality of Life 2Nivolumab 2Molecular Diagnostic Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × sapanisertib × Sarcoma × Clear all
NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡